- Home
- CWAN vs PCVX Comparison
CWAN vs PCVX Comparison
Compare CWAN & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CWAN | PCVX |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.1B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CWAN | PCVX |
|---|---|---|
| Price | $23.57 | $61.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $25.09 | ★ $98.33 |
| AVG Volume (30 Days) | ★ 10.7M | 1.3M |
| Earning Date | 05-21-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $731,368,000.00 | N/A |
| Revenue This Year | $31.86 | N/A |
| Revenue Next Year | $18.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 61.88 | N/A |
| 52 Week Low | $15.74 | $28.09 |
| 52 Week High | $30.85 | $76.61 |
Technical Indicators
Market Signals| Indicator | CWAN | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 61.94 |
| Support Level | $23.22 | $42.30 |
| Resistance Level | $24.33 | $65.00 |
| Average True Range (ATR) | 0.27 | 3.12 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 83.63 | 69.20 |
Price Performance
Historical ComparisonAbout CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.